EAM Investors’s Mirum Pharmaceuticals MIRM Stock Holding History

EAM Investors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.02M	Sell	42,860 -733	-2%	-$73.6K	0.45%	103
2026 Q1	$4.03M	Sell	43,593 -4,473	-9%	-$421K	0.46%	93
2025 Q4	$3.8M	Sell	48,066 -15,011	-24%	-$1.08M	0.42%	125
2025 Q3	$4.55M	Buy	+63,077	New	+$4.01M	0.52%	78
2025 Q2	–	Sell	-72,678	Closed	-$3.27M	–	310
2025 Q1	$3.27M	Sell	72,678 -278	-0.4%	-$13.1K	0.57%	82
2024 Q4	$3.02M	Sell	72,956 -22,465	-24%	-$936K	0.43%	120
2024 Q3	$3.72M	Buy	+95,421	New	+$3.81M	0.56%	93
2022 Q3	–	Sell	-95,607	Closed	-$1.86M	–	303
2022 Q2	$1.86M	Buy	95,607 +40,967	+75%	+$966K	0.45%	80
2022 Q1	$1.2M	Buy	+54,640	New	+$1.11M	0.22%	230
2020 Q2	–	Sell	-53,832	Closed	-$754K	–	295
2020 Q1	$754K	Buy	53,832 +7,046	+15%	+$116K	0.23%	175
2019 Q4	$1.15M	Buy	+46,786	New	+$499K	0.25%	181

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors's MIRM Position: Q2 2026 in Review

EAM Investors reduced its Mirum Pharmaceuticals (MIRM) stake by 1.7% in Q2 2026, selling an estimated $73.6K and leaving 42,860 shares worth $5.02M. The position accounts for 0.45% of the portfolio, ranked #103.

EAM Investors first reported a position in MIRM in Q4 2019 and has held it in 11 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

EAM Investors held 42,860 shares of Mirum Pharmaceuticals worth $5.02M as of Q2 2026.
EAM Investors sold 733 Mirum Pharmaceuticals shares in Q2 2026, an estimated $73.6K.
Mirum Pharmaceuticals made up 0.45% of EAM Investors's portfolio in Q2 2026, its #103 holding.
EAM Investors first reported a position in Mirum Pharmaceuticals in Q4 2019 and has held it in 11 quarters since.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.